Upstream Manufacturing Solutions

  1. Minimize Spillover Spread And Improve Panel Resolution 12/5/2025

    Unlock cleaner flow cytometry data with engineered fluorochromes that reduce spillover and boost resolution. Design complex panels easily across conventional and spectral systems.

  2. Expand Your T-Cell Research With Confidence 12/5/2025

    Achieve deeper T-cell characterization with a panel designed for flexibility. Streamline multicolor panel design, see higher resolution markers, and enable intracellular cytokine detection together.

  3. Phosphitylating And Phosphorylating Agents 11/25/2025

    Explore essential phosphitylating and phosphorylating agents used in API synthesis and oligonucleotide preparation for cell and gene therapy applications.

  4. Oligonucleotide Manufacturing: End-To-End Solutions To Enable Large-Scale Processing 11/24/2025

    Discover end-to-end solutions for challenging large-scale oligonucleotide manufacturing. Optimize processes across the entire value chain to enable ultra-high purity and cost-effective commercialization.

  5. CHO Edge System 11/24/2025

    Achieve high monoclonal antibody and complex bispecific titers routinely with an IND-approved cell line development platform that integrates genetic tools and data-driven models.

  6. LV Edge System 11/24/2025

    By transitioning from a 4-plasmid transient system to 1- or 0-plasmid configurations, the LV Edge systems reduce or eliminate the need for GMP plasmids, lowering costs and supply chain risks.

  7. AAV Edge System 11/24/2025

    Learn about a modular tool suite capable of achieving titers up to 6E15 vg/L. Move from transfection to stable cell lines in just 20 weeks using AI-driven optimization and robust host platforms.

  8. Powering Production Of Viral Vector-Based Therapies 11/14/2025

    Gene therapies hold immense potential to provide long-lasting treatments for a wide range of diseases. At Cytiva, we offer GMP-compliant, end-to-end manufacturing solutions designed to support the development and commercialization of advanced medicines across multiple modalities – including AAV, adenovirus (AV), lentivirus (LV), plasmid DNA (pDNA) and exosomes. Our dependable suite of technologies and expertise ensures scalability, quality, and regulatory confidence at every stage of your journey.

  9. Media By Design: Gibco CHO Media And Feed Panel Evaluations 11/14/2025

    Leverage diverse, ready-to-use media and feed formulations to quickly identify the optimal nutrient balance for your CHO cell line, accelerating bioproduction success and subsequent process optimization.

  10. Custom Media Development Services 11/14/2025

    Leverage custom media development services to optimize formulations for increased titers, quality, and manufacturability. Choose between traditional or multi-omics workflows to meet your cell line's specific needs.